Pharmaxis

Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases. Our first product, Aridol, is now registered for sale in the United States, Europe, Australia and South East Asia. Aridol is designed to detect bronchial hyperresponsiveness and assist in the management of asthma. Our second product, Bronchitol, an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe. We are committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that's built to last.